Drugs / VX-814
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04167345 | Jan → Nov 2020 | alpha 1-antitrypsin deficiency | Vertex Pharmaceuticals Incorporated | Terminated | Met primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2020-10-14 | Vertex Pharmaceuticals Incorporated | Results Vertex Provides Update on its Clinical Programs Targeting Alpha-1 Antitrypsin Deficiency vrtx.com ↗
Based on the safety and pharmacokinetic (PK) profile of VX-814 observed to date in a Phase 2 trial in AATD, Vertex has decided to stop dosing in the trial and will discontinue development of VX-814. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2020-10-14 | Vertex Pharmaceuticals Incorporated | Vertex Provides Update on its Clinical Programs Targeting Alpha-1 Antitrypsin Deficiency vrtx.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VX-814 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04167345 ↗ |
| Route | Oral | “Tablet for oral administration.” NCT04167345 ↗ |